Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;43(1):40-4.
doi: 10.4103/0253-7613.75667.

Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial

S Chatterjee  1 , T Biswas, A Dutta, G Sengupta, A Mitra, S Kundu
Affiliations

Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial

S Chatterjee et al. Indian J Pharmacol. 2011 Feb.

Abstract

Objective: Acute exacerbation of chronic bronchitis (AECB) is a commonly encountered problem and those suspected to be due to bacterial infections require antibiotic therapy. This randomized, controlled trial was designed to evaluate the effectiveness and safety of gemifloxacin, a new fluoroquinolone, versus cefpodoxime, an oral third-generation cephalosporin, for the treatment of mild to moderately severe cases of AECB.

Materials and methods: Adult subjects diagnosed with chronic bronchitis with clinical symptoms suggestive of an Anthonisen type II acute exacerbation (any two of the following criteria - increased dyspnea, cough, sputum purulence) were eligible and those fulfilling the subject selection criteria were randomized to receive either gemifloxacin 320 mg once daily or cefpodoxime 200 mg twice daily orally for 7 days. The primary outcome measure was clinical success rate at day 14 visit and the secondary outcome measures were changes in Clinical Global impression (CGI) scales and incidence of adverse events (AEs). Fifty-two subjects were enrolled: 26 in gemifloxacin group and 24 in the other and 2 were lost to follow-up.

Results: The clinical success rates were comparable (84.6% in gemifloxacin group versus 83.3% in cefpodoxime group) and no statistically significant difference was observed between the groups. AEs were mild, self-limiting and few (two in gemifloxacin and three in cefpodoxime arm) and tolerability was also good.

Conclusion: The results of this randomized, single-blind trial demonstrated that a 7-day course of gemifloxacin is therapeutically comparable to cefpodoxime in terms of both clinical effectiveness and safety for the treatment of type II Anthonisen category AECB patients.

Keywords: Acute exacerbation of chronic bronchitis; cefpodoxime; clinical trial; gemifloxacin.

PubMed Disclaimer

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Workshop Report. Bethesda, MD: DHHS, National Institutes of Health, 2001; NIH Publication No. 2701. Available from: http://www.goldcopd.com [last accessed on 2008 Jul 18]
    1. Reilly JJ, Silverman EK, Shapiro SD. Chronic obstructive pulmonary disease. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 17th ed. Vol 2. New York: McGraw-Hill; 2008. pp. 1635–43.
    1. Jivcu C, Gotfried M. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2009;4:291–300. - PMC - PubMed
    1. Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: A new flouroquinolone approved for treatment of respiratory infections. Ann Pharmacother. 2004;38:1226–35. - PubMed
    1. Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line versus second-line antibiotics for acute exacerbation of chronic bronchitis. A meta analysis of randomized controlled trials. Chest. 2007;132:447–55. - PubMed